StreetInsider.com News Articles

Form 6-K Agomab Therapeutics NV For: May 27

Wed, 27 May 2026 07:12:00 -0400

si-local-file:///var/storage/secattach/20260527/26553443.html

Agomab Announces Results of Annual General Meeting

Wed, 27 May 2026 05:00:00 -0400

Antwerp, Belgium, May 27, 2026 – Agomab Therapeutics NV (Nasdaq: AGMB) (“Agomab”), a clinical-stage biopharmaceutical company focused on fibro-inflammation, today announced the results of its Annual General Meeting (AGM) held on Tuesday, May 26, 2026.

All items on the agenda were approved, including:

Approval of the statutory financial statements for the financial year ended December 31, 2025.
Discharge to the current and former members of the Board of Directors and the statutory auditor in respect of the performance of their respective duties during the financial year ending on December 31, 2025.
Reappointment of Mr. Ohad

Agomab Announces Results of Annual General Meeting

Wed, 27 May 2026 05:00:00 -0400

Approval of the statutory financial statements for the financial year ended December 31, 2025.
Discharge to the current and former members of the Board of Directors and the statutory auditor in respect of the performance of their respective duties during the financial year ending on December 31, 2025.
Reappointment of Mr. Ohad

Agomab Announces Results of Annual General Meeting

Wed, 27 May 2026 05:00:00 -0400

Approval of the statutory financial statements for the financial year ended December 31, 2025.
Discharge to the current and former members of the Board of Directors and the statutory auditor in respect of the performance of their respective duties during the financial year ending on December 31, 2025.
Reappointment of Mr. Ohad Hammer as

Agomab Announces Results of Annual General Meeting

Wed, 27 May 2026 05:00:00 -0400

Approval of the statutory financial statements for the financial year ended December 31, 2025.
Discharge to the current and former members of the Board of Directors and the statutory auditor in respect of the performance of their respective duties during the financial year ending on December 31, 2025.
Reappointment of Mr. Ohad Hammer as

Form SCHEDULE 13G Agomab Therapeutics NV Filed by: Redmile Group, LLC

Fri, 15 May 2026 16:49:00 -0400

si-local-file:///var/storage/secattach/20260515/26507227.html

Form SCHEDULE 13G Agomab Therapeutics NV Filed by: Cormorant Asset Management, LP

Fri, 15 May 2026 13:15:00 -0400

si-local-file:///var/storage/secattach/20260515/26503180.html

Agomab to Participate in Upcoming Conferences

Thu, 14 May 2026 07:30:00 -0400

Antwerp, Belgium, May 14, 2026 – Agomab Therapeutics NV (Nasdaq: AGMB) (“Agomab”), a clinical-stage biopharmaceutical company focused on fibro-inflammation, today announced that members of the management team will participate in the following upcoming industry and investor conferences:

ATS International Conference 2026. Poster Board #904 titled ‘AGMB-447, an Inhaled Lung-Restricted TGFβR1/ALK5 Inhibitor Intended for the Treatment of Idiopathic Pulmonary Fibrosis, Shows Robust Anti-Fibrotic Activity and Target Engagement in Preclinical Species and Healthy Subjects’ on Wednesday, May 20, 2026 at 8:15 AM ET in Orlando, FL.
H.C. Wainwright 4th Annual BioConnect Investor Conference at

Agomab to Participate in Upcoming Conferences

Thu, 14 May 2026 07:30:00 -0400

Antwerp, Belgium, May 14, 2026 – Agomab Therapeutics NV (Nasdaq: AGMB) (“Agomab”), a clinical-stage biopharmaceutical company focused on fibro-inflammation, today announced that members of the management team will participate in the following upcoming industry and investor conferences:

ATS International Conference 2026. Poster Board #904 titled ‘AGMB-447, an Inhaled Lung-Restricted TGFβR1/ALK5 Inhibitor Intended for the Treatment of Idiopathic Pulmonary Fibrosis, Shows Robust Anti-Fibrotic Activity and Target Engagement in Preclinical Species and Healthy Subjects’ on Wednesday, May 20, 2026 at 8:15 AM ET in Orlando, FL.

H.C. Wainwright 4th Annual BioConnect Investor Conference at

Form SCHEDULE 13G Agomab Therapeutics NV Filed by: Sanofi

Wed, 06 May 2026 06:08:00 -0400
si-local-file:///var/storage/secattach/20260506/26438260.html

Form 6-K Agomab Therapeutics NV For: Apr 24

Fri, 24 Apr 2026 16:22:00 -0400
si-local-file:///var/storage/secattach/20260424/26366509.html

Form 20-F Agomab Therapeutics NV For: Dec 31

Thu, 23 Apr 2026 18:56:00 -0400

http://archive.fast-edgar.com/20260423/AOB23G2C8Z22EZZZ279D2ZZZTWCOR2X2Z282

Filed on: April 23, 2026

Agomab Reports Full Year 2025 Financial Results and Confirms 2026 Outlook

Thu, 23 Apr 2026 18:14:00 -0400

-- Cash and Cash Investments at December 31, 2025 of €116.5 Million and Gross Proceeds of $208 Million from Initial Public Offering (IPO) Expected to Extend Cash Runway into First Half of 2029 --

-- Positive Interactions with U.S. Food and Drug Administration (FDA) on Design of Phase 2b Study with Ontunisertib in Fibrostenosing Crohn’s Disease (FSCD) --

-- On Track to Initiate Phase 2b Study in FSCD with Ontunisertib and Phase 2 Study in Idiopathic Pulmonary Fibrosis (IPF) with AGMB-447 in Second Half of 2026 --

-- Topline Data from Open-Label Long-term Extension Study (OLE) Part of STENOVA

Agomab Reports Full Year 2025 Financial Results and Confirms 2026 Outlook

Thu, 23 Apr 2026 18:14:00 -0400

-- Cash and Cash Investments at December 31, 2025 of €116.5 Million and Gross Proceeds of $208 Million from Initial Public Offering (IPO) Expected to Extend Cash Runway into First Half of 2029 --

-- Positive Interactions with U.S. Food and Drug Administration (FDA) on Design of Phase 2b Study with Ontunisertib in Fibrostenosing Crohn’s Disease (FSCD) --

-- On Track to Initiate Phase 2b Study in FSCD with Ontunisertib and Phase 2 Study in Idiopathic Pulmonary Fibrosis (IPF) with AGMB-447 in Second Half of 2026 --

-- Topline Data from Open-Label Long-term Extension Study (OLE) Part of STENOVA

Agomab Reports Full Year 2025 Financial Results and Confirms 2026 Outlook

Thu, 23 Apr 2026 18:14:00 -0400

-- Cash and Cash Investments at December 31, 2025 of €116.5 Million and Gross Proceeds of $208 Million from Initial Public Offering (IPO) Expected to Extend Cash Runway into First Half of 2029 --

-- Positive Interactions with U.S. Food and Drug Administration (FDA) on Design of Phase 2b Study with Ontunisertib in Fibrostenosing Crohn’s Disease (FSCD) --

-- On Track to Initiate Phase 2b Study in FSCD with Ontunisertib and Phase 2 Study in Idiopathic Pulmonary Fibrosis (IPF) with AGMB-447 in Second Half of 2026 --

-- Topline Data from Open-Label Long-term Extension Study (OLE) Part of STENOVA

Agomab Reports Full Year 2025 Financial Results and Confirms 2026 Outlook

Thu, 23 Apr 2026 18:14:00 -0400

-- Cash and Cash Investments at December 31, 2025 of €116.5 Million and Gross Proceeds of $208 Million from Initial Public Offering (IPO) Expected to Extend Cash Runway into First Half of 2029 --

-- Positive Interactions with U.S. Food and Drug Administration (FDA) on Design of Phase 2b Study with Ontunisertib in Fibrostenosing Crohn’s Disease (FSCD) --

-- On Track to Initiate Phase 2b Study in FSCD with Ontunisertib and Phase 2 Study in Idiopathic Pulmonary Fibrosis (IPF) with AGMB-447 in Second Half of 2026 --

-- Topline Data from Open-Label Long-term Extension Study (OLE) Part of STENOVA

Agomab Reports Full Year 2025 Financial Results and Confirms 2026 Outlook

Thu, 23 Apr 2026 18:14:00 -0400

-- Cash and Cash Investments at December 31, 2025 of €116.5 Million and Gross Proceeds of $208 Million from Initial Public Offering (IPO) Expected to Extend Cash Runway into First Half of 2029 --

-- Positive Interactions with U.S. Food and Drug Administration (FDA) on Design of Phase 2b Study with Ontunisertib in Fibrostenosing Crohn’s Disease (FSCD) --

-- On Track to Initiate Phase 2b Study in FSCD with Ontunisertib and Phase 2 Study in Idiopathic Pulmonary Fibrosis (IPF) with AGMB-447 in Second Half of 2026 --

-- Topline Data from Open-Label Long-term Extension Study (OLE) Part of STENOVA

Agomab Reports Full Year 2025 Financial Results and Confirms 2026 Outlook

Thu, 23 Apr 2026 18:14:00 -0400

-- Cash and Cash Investments at December 31, 2025 of €116.5 Million and Gross Proceeds of $208 Million from Initial Public Offering (IPO) Expected to Extend Cash Runway into First Half of 2029 --

-- Positive Interactions with U.S. Food and Drug Administration (FDA) on Design of Phase 2b Study with Ontunisertib in Fibrostenosing Crohn’s Disease (FSCD) --

-- On Track to Initiate Phase 2b Study in FSCD with Ontunisertib and Phase 2 Study in Idiopathic Pulmonary Fibrosis (IPF) with AGMB-447 in Second Half of 2026 --

-- Topline Data from Open-Label Long-term Extension Study (OLE) Part of STENOVA

Form SCHEDULE 13G Agomab Therapeutics NV Filed by: Pontifax Management 4 G.P. (2015) Ltd.

Thu, 16 Apr 2026 09:14:00 -0400
si-local-file:///var/storage/secattach/20260416/26322272.html

Agomab receives US patent for lung fibrosis drug candidate AGMB-447

Thu, 26 Mar 2026 07:01:33 -0400

Agomab Therapeutics NV (NASDAQ: AGMB) announced the United States Patent and Trademark Office granted U.S. Patent No. 12,577,230 covering the composition of matter for AGMB-447. The patent provides intellectual property protection for the drug candidate in the United States through at least 2041, excluding potential patent term extensions.
AGMB-447 is an investigational inhaled small molecule inhibitor of ALK5 currently in a Phase 1b study for treating Idiopathic Pulmonary Fibrosis. The drug candidate is designed to inhibit ALK5 in the lung while avoiding systemic exposure through local administration via inhalation and rapid breakdown in plasma.
"The issuance of this patent is a significant

Agomab Receives U.S. Patent for AGMB-447, its Inhaled Lung-restricted Small Molecule Inhibitor of ALK5 in Development for the Treatment of Idiopathic Pulmonary Fibrosis

Thu, 26 Mar 2026 07:00:00 -0400

Antwerp, Belgium, March 26, 2026 – Agomab Therapeutics NV (Nasdaq: AGMB) (“’Agomab’”), a clinical-stage biopharmaceutical company focused on fibrosis, today announced that the United States Patent and Trademark Office (USPTO) has granted U.S. Patent No. 12,577,230, covering the composition of matter of AGMB-447, to Agomab. AGMB-447 is the company’s investigational inhaled lung-restricted small molecule inhibitor of ALK5 (or TGFβR1), currently in a Phase 1b study for the treatment of Idiopathic Pulmonary Fibrosis (IPF). This patent provides intellectual property (IP) protection for AGMB-447 in the U.S. through at least 2041, excluding any potential patent term extensions.

Agomab Receives U.S. Patent for AGMB-447, its Inhaled Lung-restricted Small Molecule Inhibitor of ALK5 in Development for the Treatment of Idiopathic Pulmonary Fibrosis

Thu, 26 Mar 2026 07:00:00 -0400

Antwerp, Belgium, March 26, 2026 – Agomab Therapeutics NV (Nasdaq: AGMB) (“’Agomab’”), a clinical-stage biopharmaceutical company focused on fibrosis, today announced that the United States Patent and Trademark Office (USPTO) has granted U.S. Patent No. 12,577,230, covering the composition of matter of AGMB-447, to Agomab. AGMB-447 is the company’s investigational inhaled lung-restricted small molecule inhibitor of ALK5 (or TGFβR1), currently in a Phase 1b study for the treatment of Idiopathic Pulmonary Fibrosis (IPF). This patent provides intellectual property (IP) protection for AGMB-447 in the U.S. through at least 2041, excluding any potential patent term extensions.

Form 3 Agomab Therapeutics NV For: Mar 18 Filed by: Wiesel Philippe Constantin

Wed, 18 Mar 2026 16:02:00 -0400
si-local-file:///var/storage/secattach/20260318/26184375.html

Form 3 Agomab Therapeutics NV For: Mar 18 Filed by: Jahreis Angelika Martha

Wed, 18 Mar 2026 16:02:00 -0400
si-local-file:///var/storage/secattach/20260318/26184377.html

Form 3 Agomab Therapeutics NV For: Mar 18 Filed by: van der Horst Paul Henryk

Wed, 18 Mar 2026 16:02:00 -0400
si-local-file:///var/storage/secattach/20260318/26184384.html